Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Challenges and opportunities in the early diagnosis and optimal management of rheumatoid arthritis in Africa and the Middle East.

Halabi H, Alarfaj A, Alawneh K, Alballa S, Alsaeid K, Badsha H, Benitha R, Bouajina E, Al Emadi S, El Garf A, El Hadidi K, Laatar A, Makhloufi CD, Masri AF, Menassa J, Al Shaikh A, Swailem RA, Dougados M.

Int J Rheum Dis. 2015 Mar;18(3):268-75. doi: 10.1111/1756-185X.12320. Epub 2014 Mar 13. Review.

PMID:
24620997
2.

Unmet needs in rheumatoid arthritis.

Bykerk V.

J Rheumatol Suppl. 2009 Jun;82:42-6. doi: 10.3899/jrheum.090131. Review.

PMID:
19509330
3.

Remission in rheumatoid arthritis: wishful thinking or clinical reality?

Sesin CA, Bingham CO 3rd.

Semin Arthritis Rheum. 2005 Dec;35(3):185-96.

PMID:
16325659
4.

Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.

Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R.

Ann Rheum Dis. 2015 Jan;74(1):27-34. doi: 10.1136/annrheumdis-2014-205489. Epub 2014 Oct 30.

PMID:
25359382
5.

Optimal use of non-biologic therapy in the treatment of rheumatoid arthritis.

Jacobs JW.

Rheumatology (Oxford). 2012 Jun;51 Suppl 4:iv3-8. doi: 10.1093/rheumatology/kes083. Epub 2012 Apr 19. Review.

PMID:
22513146
6.

Core management principles in rheumatoid arthritis to help guide managed care professionals.

Agarwal SK.

J Manag Care Pharm. 2011 Nov-Dec;17(9 Suppl B):S03-8. Review.

PMID:
22073933
7.

Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis.

Sandberg ME, Bengtsson C, Källberg H, Wesley A, Klareskog L, Alfredsson L, Saevarsdottir S.

Ann Rheum Dis. 2014 Nov;73(11):2029-33. doi: 10.1136/annrheumdis-2013-205094. Epub 2014 May 12.

PMID:
24818635
8.

Assessment and management of rheumatoid arthritis.

Haraoui B.

J Rheumatol Suppl. 2009 Jun;82:2-10. doi: 10.3899/jrheum.090124. Review. Erratum in: J Rheumatol. 2009 Aug;36(8):1851.

PMID:
19509324
9.

Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?

Ciubotariu E, Gabay C, Finckh A; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.

J Rheumatol. 2014 Aug;41(8):1576-82. doi: 10.3899/jrheum.130767. Epub 2014 Jul 15.

PMID:
25028383
10.

Drug management of early rheumatoid arthritis - 2008.

Sokka T, Mäkinen H.

Best Pract Res Clin Rheumatol. 2009 Feb;23(1):93-102. doi: 10.1016/j.berh.2008.08.003. Review.

PMID:
19233049
11.

Current concepts in the management of rheumatoid arthritis.

Tanaka Y.

Korean J Intern Med. 2016 Mar;31(2):210-8. doi: 10.3904/kjim.2015.137. Epub 2016 Feb 26. Review.

12.

Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.

Gaujoux-Viala C, Smolen JS, Landewé R, Dougados M, Kvien TK, Mola EM, Scholte-Voshaar M, van Riel P, Gossec L.

Ann Rheum Dis. 2010 Jun;69(6):1004-9. doi: 10.1136/ard.2009.127225. Epub 2010 May 6. Review.

PMID:
20447954
13.

Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register.

Rheumatology (Oxford). 2006 Dec;45(12):1558-65. Epub 2006 May 16.

PMID:
16705046
14.

Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.

Nikolaisen C, Kvien TK, Mikkelsen K, Kaufmann C, Rødevand E, Nossent JC.

Scand J Rheumatol. 2009;38(4):240-5. doi: 10.1080/03009740802609566.

PMID:
19229766
15.

The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort.

Benhamou M, Rincheval N, Roy C, Foltz V, Rozenberg S, Sibilia J, Schaeverbeke T, Bourgeois P, Ravaud P, Fautrel B.

J Rheumatol. 2009 May;36(5):934-42. doi: 10.3899/jrheum.080762. Epub 2009 Mar 13.

16.

Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide.

Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS.

Ann Rheum Dis. 2002 Apr;61(4):290-7. Review.

17.
18.

Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis.

Demoruelle MK, Deane KD.

Curr Rheumatol Rep. 2012 Oct;14(5):472-80. doi: 10.1007/s11926-012-0275-1. Review.

19.

Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs.

Sizova L.

Br J Clin Pharmacol. 2008 Aug;66(2):173-8. doi: 10.1111/j.1365-2125.2008.03222.x. Epub 2008 May 15. Review.

20.

Predictors for low disease activity and remission in rheumatoid arthritis patients treated with biological DMARDs.

Wacharapornin P, Suwannalai P.

J Med Assoc Thai. 2014 Nov;97(11):1157-63.

PMID:
25675680

Supplemental Content

Support Center